Improving the predictive accuracy of efficacy evaluation using tumor orthotopic transplant and resection model

Xiaoxi Li ¹, Lingli Luo ¹, Hui Qian ¹

⁰Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China.

Frontiers in Pharmacology +

|

March 13, 2024

View abstract on PubMed

Summary

Accurate preclinical efficacy evaluation is crucial for cancer drug development. New indicators using orthotopic transplant models can better predict overall survival benefit by assessing tumor recurrence and metastasis, not just growth inhibition.

Area Of Science

Oncology
Drug Development
Translational Medicine

Background

Preclinical efficacy evaluation and tumor drug sensitivity analysis are key applications in cancer research.
Overall survival (OS) is the gold standard for evaluating anti-cancer drugs and therapies.
Current models often focus on tumor growth inhibition, potentially overlooking treatment-induced malignant progression like metastasis.

Purpose Of The Study

To address the limitations of existing preclinical models in predicting clinical outcomes.
To propose improved efficacy evaluation indicators that better correlate with overall survival (OS) benefit.
To accelerate the development of effective anti-cancer drugs and optimize treatment regimens.

Main Methods

Review of current understanding of tumor recurrence and metastasis pathology.
Critique of existing tumor transplant models for simulating clinical malignant progression.
Proposal of five novel indicators for comprehensive efficacy evaluation using tumor orthotopic transplant and resection models.

Main Results

Existing models inadequately simulate clinical scenarios of tumor malignant progression.
Tumor growth inhibition does not always correlate with improved overall survival (OS).
Recurrence and metastasis prevention are critical determinants of therapeutic benefit.

Conclusions

Improved efficacy evaluation indicators are needed to accurately predict OS benefit.
The proposed indicators using orthotopic models offer a more comprehensive assessment.
Enhanced preclinical evaluation will accelerate drug development and reduce costs for cancer therapies.

Keywords:

OS benefit efficacy evaluation model neoadjuvant therapy and adjuvant therapy preclinical efficacy evaluation tumor drug sensitivity analysis tumor local recurrence and distant metastasis tumor orthotopic transplant and resection model